PLX4032 (Vemurafenib) is an 7-azaindole-based, orally-available, inhibitor of the B-Raf V600E mutation with an IC50 of 30 nM. [1] In preclinical tumor models, PLX4032 induces antiproliferative effects in both mealonama and thyroid cell lines, with a simultaneous dose-dependent block of MEK1/2 phosphorylation. [1] Apoptosis is also observed in melanoma cell lines upon treatment with PLX4032. Important to note is that proliferation was inhibited in tumor cell lines expressing B-Raf V600E only, and not B-Raf WT or other B-Raf mutations. [2]PLX4032 has marginal effect on cell-cycle arrest, apoptotic cell changes, or alteration of phosphorylated signaling molecules in lymphocytes. T-cell function was preserved up to 10 uM of PLX4032, while cytotoxic activty was maintained up to high concentrations of 50 uM. [3] Such observations suggest that PLX4032 can be used in combination with immunotherapy strategies.

Technical information:

Shipping Condition: The product is shipped in a glass vial at ambient temperature.Storage condition: For longer shelf life, store solid powder at 4^oC desiccated, or store DMSO solution at -20^oC.

Reference:

Other Information:

Product Specification (pdf) MSDS (pdf) Certificate of Analysis is available upon request.

Cellagen利用广泛的研究以及我们在干细胞生物学，药物化学和产品开发方面的专业知识，Cellagen长期以来一直为专业OEM产品提供世界领先的公司，为一线干细胞研究奠定了基础。

现在，Cellagen扩展了其最佳产品系列，并直接向研究界提供。Cellagen与世界领先的科学家有着密切的联系，并且始终认识到高标准科学研究的未满足需求。